UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): December 20, 2001
Hadron, Inc.
(Exact name of registrant as specified in its charter)
New York 0-5404 11-2120726
- ----------------------------------------------- ------------------------ ---------------------------------
(State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)
5904 Richmond Highway, Suite 300, Alexandria, VA 22309
- -------------------------------------------------- --------------
(Address of principal executive offices) (Zip Code)
(703) 329-9400
---------------------------------------------------
(Registrant's telephone number, including area code)
N/A
- -------------------------------------------------------------------------------
(Former name, former address and former fiscal year,
if changed since last report)
Item 5. Other Events.
Hadron, Inc. (OTC:BB:HDRN) issued a press release on December 20, 2001
regarding the research and development strategies being pursued by its Advanced
Biosystems, Inc. subsidiary. A copy of the press release is attached as an
exhibit.
Item 7. Financial Statements and Exhibits
(c) Press Release dated December 20, 2001 is included herein as
Exhibit 99.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned, hereunto duly authorized.
HADRON, INC.
Date: December 20, 2001 By: /s/ Sterling Phillips
----------------------------
Sterling Phillips
Chief Executive Officer
INDEX TO EXHIBITS
Exhibit No. Exhibit
- ----------- -------
99 Press Release dated December 20, 2001